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Ventilator associated pneumonia (VAP) is recognised as one of the most frequent nosocomial infection in 
Intensive Care Unit (ICU), with infection rates varying from 10-30% of mechanically ventilated patients.1-3 
VAP is undoubtedly a burden on the health care system and has been associated with adverse patient outcomes; 
increases in ICU Length of stay (LOS), hospital LOS and crudely associated with increased mortality.1, 4 
Furthermore, it has been widely reported to impact on health care resources resulting in significant inflation of 
health care costs.5-7 
 
VAP is broadly defined as pneumonia in persons who have had an invasive device, an endotracheal tube or 
tracheostomy, to assist ventilation continuously for at least 48hrs. Although, the devil is in the detail when 
applying the definition for quality surveillance purposes and its lack of objectivity and variability in 
interpretation is proving problematic for the critical care community. At present, there is little consensus on an 
effective surveillance definition for Ventilator Associated Pneumonia (VAP). Varying definitions and 
terminology have existed over time, notably The Centres for Disease Control and Prevention (CDC) provide the 
most widely-used and reported definition for VAP surveillance. The complexity of the previous definition,3 and 
lack of objectivity and sensitivity has posed doubt over its reliability as a benchmarking tool.8  
 
The CDC addressed these limitations in September 2011 by establishing a VAP Surveillance Working Group, 
consisting of clinical experts and stakeholders in the field.9 Accordingly a revised three tiered definition to be 
used for surveillance of Ventilator Associated Events (VAE) was introduced by the CDC in January 2013.10 In 
light of the changing definition, the PAH (Princess Alexandra Hospital) ICU Quality Taskforce recognised the 
potential impact of the change in definitions on benchmarking activities and undertook a unit based comparison 
of the 2009 and 2013 definitions. We hypothesised little concordance between patients classified as VAP 
(PNU1-Clinically defined pneumonia, PNU2-Pneumonia with specific laboratory findings, PNU3-Pneumonia in 
immunocompromised patients) according to the 2009 definition compared to patients diagnosed with VAE 
(Ventilator Associated Event) (VAC-Ventilator Associated Condition, IVAC-Infection-Related Ventilator-
Associated Complication, Possible VAP or Probable VAP) on the 2013 criteria (Table 1). 
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Table 1: Comparison of 2009 and 2013 VAP/VAE definitions  
CDC 2009 Definition: Ventilator Associated 
Pneumonia (VAP) 
CDC 2013 Definition: Ventilator Associated Event 
(VAE) 
• All mechanically ventilated patients with positive 
Chest X-Ray reports (new or progressive and 
persistent infiltrates, consolidation or cavitation)  
• Temp >38° and/or WCC <4.0 x 10⁹/L or >12.0 x 
10⁹/L 
• At least two respiratory symptoms of tachypnoea 
or dyspnoea, rales or bronchial breath sounds, 
worsening gas exchange (PaO2/FiO2 ≤240), 
evidence of new onset of purulent sputum 
(leukocytes 2+) and/or cough, and/or pleuritic 
chest pain or haemoptysis (in 
immunocompromised patients) or >70 years with 
an altered mental status.  
NB. Patients were excluded if they were admitted with 
a respiratory infection, or if there was a likelihood of 
aspiration pre intubation by a modified rule (a GCS <8 
documented pre intubation). 
• Patients with ≥2 calendar days of stable 
ventilation prior to a sustained period of ≥2 
calendar days of worsening oxygenation indicated 
by an increase in FiO2 ≥0.2 and/or increase in 
daily minimum PEEP ≥3cmH2O  
• Temp>38°C or < 36°C, and/or WCC <4.0 x 10⁹/L 
or >12.0 x 10⁹/L  
• A new antimicrobial agent commenced and 
continued for ≥4 calendar days.  
• Purulent respiratory secretions (leukocytes 2+) 
and/or a positive culture of sputum, endotracheal 
aspirate, bronchoalveolar lavage, lung tissue or 
protected specimen brushing. 
 
All mechanically ventilated patients admitted to the PAH General ICU over a three month period, April to June 
2013 (n= 253), were assessed by one of three ICU trained Quality Clinical Nurses for each of the criteria for the 
diagnosis of PNU 1, 2 or 3 (2009 VAP) or VAC, IVAC, Possible / Probable VAP (2013 VAE); this assessment 
was then reviewed by at least one of three Consultant Intensivists who were designated members of the ICU 
Quality Taskforce. Ethical approval was received from Metro South Human Research Ethics Committee.  
 
Patients were 53.1 (SD 19.3) years old; two thirds (67%) male; had a median (IQR) APACHE II of 18 (12-22) 
and stayed in ICU median (IQR) 3 (1-7) days. ICU mortality was 10.3%, while hospital mortality was 14.6%. 
Two patients satisfied the 2009 criteria (VAP rate 1.8/1000 ventilator days) while six different patients from the 
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Table 2: Characteristics of patients diagnosed with VAP/VAE 
Day: Day of ICU admission when VAP/VAE diagnosis made  
 
In this cohort of mechanically ventilated patients from a tertiary hospital there was no concordance between 
VAP and VAE data representing the first known report of this discrepancy in the Australian setting; this finding 
is consistent with international reports11, 12 and suggests that VAP and VAE surveillance data are not 
interchangeable. The problem of inconsistency in diagnosis or surveillance rates has also been demonstrated 
across a range of six different sets of diagnostic criteria, 13 with the incidence of VAP ranging from 4 – 42%. 
These findings also support the notion that surveillance rates can be manipulated depending on which criteria 
you use and initiatives designed to increase the rigour of surveillance can have the effect of biasing VAP rates. 
14 Use of both these definitions for quality surveillance has proven to be labour intensive, and given the 
ambiguity in both diagnosis and relationship to outcome, scrutiny of whether this is the best use of resources is 
essential.  
 
A lack of consistency in surveillance rates dependent on which definitions are used means that comparison over 
time, or between institutions on a national or international scale, is not possible unless everyone agrees to use 
the same criteria. Further, use of these data in public reporting or to fund or penalise healthcare organisations is 
not possible until there has been development and agreement of criteria that are less subjective and examination 
of the subsequent impact of outcomes.15, 16  
VAP 1.8/1000 ventilator days VAE 5.6/1000 ventilator days 
VAP 
Classification 




AGE Day  LOS Admission 
Diagnosis 
PNU1 34 11 38 Spinal/Multi 
trauma 
VAC 51 9 17 Neurological 
Encephalitis 




VAC 34 5 12 Trauma 
Chest/extremity  
     IVAC 62 27 81 Coronary artery 
bypass grafting 
     IVAC 32 3 28 Trauma Isolated 
cervical spine 
injury 
     IVAC 46 7 25 Gastrointestinal 
GI Abscess/cyst 
     Probable VAP 19 5 14 Trauma Isolated 
cervical spine 
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